Azeliragon HCl

Azeliragon free base, also known as TTP488 and PF-04494700, is a potent and orally active RAGE inhibitor. RAGE (receptor for advanced glycation endproducts) is a pattern recognition receptor, which affects the movement of amyloid, an Alzheimer's-associated protein, into the brain. In preclinical studies, azeliragon decreased brain amyloid in mice and improved their performance on behavior tests. Azeliragon is a promising agent for for Alzheimer's disease and cerebral amyloid angiopathy.

Product information

CAS Number: 1284150-65-7

Molecular Weight: 605.04

Formula: C32H40Cl3N3O2

Synonym:

Azeliragon hydrochloride

Azeliragon dihydrochloride

PF-04494700

TTP-488

Azeliragon HCl

TTP488 HCl

TTP 488

PF 04494700

PF04494700

Chemical Name: 3-(4-(2-butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethylpropan-1-amine dihydrochloride

Smiles: Cl.Cl.CCCCC1=NC(=CN1C1C=CC(=CC=1)OC1C=CC(Cl)=CC=1)C1C=CC(=CC=1)OCCCN(CC)CC

InChiKey: CQAGJWKITXAOAM-UHFFFAOYSA-N

InChi: InChI=1S/C32H38ClN3O2.2ClH/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29;;/h10-21,24H,4-9,22-23H2,1-3H3;2*1H

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

References:

1. Wautier MP, Guillausseau PJ, Wautier JL. Activation of the receptor for advanced glycation end products and consequences on health. Diabetes Metab Syndr. 2016 Sep 4. pii: S1871-4021(16)30208-9. doi: 10.1016/j.dsx.2016.09.009. [Epub ahead of print] Review. PubMed PMID: 27612394.
2. Godyń J, Jończyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Rep. 2016 Feb;68(1):127-38. doi: 10.1016/j.pharep.2015.07.006. Epub 2015 Aug 5. Review. PubMed PMID: 26721364.

Products are for research use only. Not for human use.